180 related articles for article (PubMed ID: 38605180)
1. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer.
Zong HF; Li X; Han L; Wang L; Liu JJ; Yue YL; Chen J; Ke Y; Jiang H; Xie YQ; Zhang BH; Zhu JW
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38605180
[TBL] [Abstract][Full Text] [Related]
2. Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor.
Zhuang W; Zhang W; Wang L; Xie L; Feng J; Zhang B; Hu Y
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003245
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
4. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
[TBL] [Abstract][Full Text] [Related]
5. Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.
de Goeij BE; Vink T; Ten Napel H; Breij EC; Satijn D; Wubbolts R; Miao D; Parren PW
Mol Cancer Ther; 2016 Nov; 15(11):2688-2697. PubMed ID: 27559142
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
7. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
8. Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer.
Douez E; Allard-Vannier E; Amar IAM; Jolivet L; Boursin F; Maisonial-Besset A; Witkowski T; Chezal JM; Colas C; Letast S; Auvert E; Denevault-Sabourin C; Aubrey N; Joubert N
J Control Release; 2024 Feb; 366():567-584. PubMed ID: 38215985
[TBL] [Abstract][Full Text] [Related]
9. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
10. HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker.
Gril B; Wei D; Zimmer AS; Robinson C; Khan I; Difilippantonio S; Overstreet MG; Steeg PS
Neuro Oncol; 2020 Nov; 22(11):1625-1636. PubMed ID: 32386414
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2.
Krzyscik MA; Porębska N; Opaliński Ł; Otlewski J
Int J Biol Macromol; 2024 Jan; 254(Pt 1):127657. PubMed ID: 38287563
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
13. PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.
Graziani EI; Sung M; Ma D; Narayanan B; Marquette K; Puthenveetil S; Tumey LN; Bikker J; Casavant J; Bennett EM; Charati MB; Golas J; Hosselet C; Rohde CM; Hu G; Guffroy M; Falahatpisheh H; Finkelstein M; Clark T; Barletta F; Tchistiakova L; Lucas J; Rosfjord E; Loganzo F; O'Donnell CJ; Gerber HP; Sapra P
Mol Cancer Ther; 2020 Oct; 19(10):2068-2078. PubMed ID: 32747418
[TBL] [Abstract][Full Text] [Related]
14. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers.
Shin SH; Park YH; Park SS; Ju EJ; Park J; Ko EJ; Bae DJ; Kim SY; Chung CW; Song HY; Jang SJ; Jeong SY; Song SY; Choi EK
Adv Sci (Weinh); 2021 Dec; 8(23):e2102414. PubMed ID: 34664433
[TBL] [Abstract][Full Text] [Related]
15. A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.
Rau A; Kocher K; Rommel M; Kühl L; Albrecht M; Gotthard H; Aschmoneit N; Noll B; Olayioye MA; Kontermann RE; Seifert O
MAbs; 2021; 13(1):1902034. PubMed ID: 33752566
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.
Lee NK; Su Y; Bidlingmaier S; Liu B
Mol Cancer Ther; 2019 Jun; 18(6):1092-1103. PubMed ID: 30962321
[TBL] [Abstract][Full Text] [Related]
17. Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.
Geuijen CAW; De Nardis C; Maussang D; Rovers E; Gallenne T; Hendriks LJA; Visser T; Nijhuis R; Logtenberg T; de Kruif J; Gros P; Throsby M
Cancer Cell; 2018 May; 33(5):922-936.e10. PubMed ID: 29763625
[TBL] [Abstract][Full Text] [Related]
18. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Pegram MD; Miles D; Tsui CK; Zong Y
Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
[TBL] [Abstract][Full Text] [Related]
20. A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2.
Hassani D; Amiri MM; Mohammadi M; Yousefi P; Judaki MA; Mobini M; Golsaz-Shirazi F; Jeddi-Tehrani M; Shokri F
Curr Res Transl Med; 2021 May; 69(2):103277. PubMed ID: 33639587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
